Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches

Table 5 Clinical trial studies targeting NAFLD-related gene variants

Targeted gene	Drug name	Mechanisms	Stage of development	Outcome	References
PNPLA3	ION839	RNA interference using antisense oligonucleotides	Phase 1	Completed	[184] NCT04142424
PNPLA3	ION839	RNA interference using antisense oligonucleotides	Phase 1	Recruiting	[184] NCT04483947
HSD17B13	ARO-HSD	Post-transcriptional gene silencing using RNAi	Phase 1	Decreased HSD17B13 mRNA Decreased HSD17B13 protein Decreased AST Decreased ALT	[189, 194] NCT04202354
HSD17B13	ALN-HSD	Post-transcriptional gene silencing using RNAi	Phase 1	Active, not recruiting	NCT04565717
HSD17B13	ALN-HSD	Post-transcriptional gene silencing using RNAi	Phase 2	Recruiting	NCT05519475
HSD17B13	AZD7503	RNA interference using antisense oligonucleotides	Phase 1	Active, not recruiting	NCT05560607
DGAT2	ION224	RNA interference using antisense oligonucleotides	Phase 2	Active, not recruiting	NCT04932512

ISSN: 2047-783X